orphan drug act law passed united states facilitate development orphan rare diseases huntingtons disease myoclonus als tourette syndrome muscular dystrophy affect small numbers individuals residing united orphan drug designation indicate therapeutic either safe effective legal manufacture market united states process handled offices us food drug administration instead designation means sponsor qualifies certain benefits federal government market exclusivity reduced taxes informal coalition supporters families patients rare diseases formed national organization rare disorders nord others called change legislation support development orphan drugs drugs treating rare succeeded getting united states congress pass orphan drug act oda early thirtyeight orphan drugs approved prior act indication designations covering drugs partly result us orphan drug act japan adopted european union response incidents difficulties thalidomide kefauverharris amendment passed amendment federal food drug cosmetic act kefauverharris required drugs approved sale proven safe effective via rigorous scientific studies legislation improved drug safety also dramatically increased costs associated developing new medicines pharmaceutical companies responded focusing developing treatments common diseases order maximize possibility recouping research development costs generating significant profits result rare diseases largely ignored due poor economic potential thus said orphaned gap drugs common versus rare diseases eventually widened point treatments available rare conditions crohns disease hansens disease orphan drugs generally follow regulatory development path pharmaceutical product testing focuses pharmacokinetics pharmacodynamics dosing stability safety efficacy however statistical burdens lessened effort maintain development momentum example orphan drug regulations generally acknowledge fact may possible test patients phase iii clinical trial fewer number may affected disease question since market drug limited application scope would definition small thus largely unprofitable government intervention often required motivate manufacturer address need orphan drug intervention government behalf orphan drug development take variety forms plight patients rare diseases became important political issue late early us government subject pressure activist groups many chief sponsor bill hr henry waxman sometimes referred author chairman energy commerce subcommittee health passed house representatives december similarly approved voice vote senate december january president ronald reagan signed oda law oda drugs vaccines diagnostic agents would qualify orphan status intended treat disease affecting less american citizens order encourage development drugs orphan diseases oda included number incentives including sevenyear market exclusivity companies developed orphan drug tax credits equal half development costs later changed fifteenyear carryforward provision threeyear carryback applied profitable year grants drug development fasttrack approvals drugs indicated rare diseases expanded access investigational new drug program law also later amended waive user fees charged market exclusivity particularly appealing pharmaceutical firms incentive pursue orphan drug development sevenyear market exclusivity period differs traditional patent law begin drug granted fda approval independent drugs current patent status furthermore market competitor wishes introduce drug indication onus competitor prove drug therapeutically superior eg increased efficacy less toxicity etc compared present drug indicated rare disease interest incentive creates attractive monopolistic market companies interested developing product given rare television historian allmovie contributor hal erickson credits two episodes television series quincy helping oda pass usa seldom silent never heard give weak shows star jack klugman even testified congress concerning orphan drug drug companies nearly universally believe oda congress enacted oda drugs approved usa specifically treat orphan us january june total different orphan drug designations granted office orphan products development oopd orphan drugs received marketing authorization contrast decade prior saw fewer ten products come market passage oda may fda approved orphan drugs granted orphan designations compounds roughly officially designated orphan diseases become drugmaker pfizer established division focus specifically development orphan large pharmaceutical companies focused greater efforts orphan drug critics questioned whether orphan drug legislation real cause increase claiming many new drugs disorders already researched anyway would drugs developed regardless legislation whether oda really stimulated production truly nonprofitable drugs act also received criticism allowing pharmaceutical companies make large profit drugs small market still sell high price orphan drug status given drugs reasonable expectation profitability orphan drugs gone net large profits andor receive widespread topic profit aftermath oda addressed november seattle times following quote pharmaceutical industry taken advantage incentives charge excessive profits reap windfalls far excess investments drug provigil orphan drug went effort reduce burden manufacturers applying orphan drug status fda ema agreed late utilize common application process agencies however two agencies continue maintain separate approval